Serious side effect of AML treatment going unnoticed, FDA warns

Print Friendly, PDF & Email


Enasidenib (Idhifa®)
Photo from Business Wire
The U.S. Food and Drug Administration (FDA) has released a safety communication warning that cases of differentiation syndrome are going unnoticed in patients treated with the IDH2 inhibitor enasidenib (Idhifa). Enasidenib is FDA-approved to treat adults with relapsed or refractory acute myeloid leukemia (AML) and an IDH2... [Read Article]
Print Friendly, PDF & Email

FDA approves venetoclax for AML

Print Friendly, PDF & Email


Venetoclax
Photo courtesy of Abbvie
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to venetoclax (Venclexta®) for use in acute myeloid leukemia (AML). The BCL-2 inhibitor is now approved for use in combination with azacitidine, decitabine, or low-dose cytarabine to treat adults with newly diagnosed AML who are age 75 and... [Read Article]
Print Friendly, PDF & Email

FDA approves glasdegib for AML

Print Friendly, PDF & Email


AML cells
Image by Lance Liotta
The U.S. Food and Drug Administration (FDA) has approved the hedgehog pathway inhibitor glasdegib (Daurismo™) to treat certain patients with acute myeloid leukemia (AML). Glasdegib is approved for use in combination with low-dose cytarabine (LDAC) to treat adults with newly diagnosed AML who are age 75 and older... [Read Article]
Print Friendly, PDF & Email

FDA approves generic drugs for APL

Print Friendly, PDF & Email


Fresenius Kabi’s
arsenic trioxide
Photo from Business Wire
The U.S. Food and Drug Administration (FDA) has now approved three generic arsenic trioxide products for use in patients with acute promyelocytic leukemia (APL). Two of the products—from Zydus Cadila and Amring Pharmaceuticals—were approved on November 13. The third—from Fresenius Kabi—was approved in August and launched... [Read Article]
Print Friendly, PDF & Email

AP-1 plays key role in various AML subtypes, team says

Print Friendly, PDF & Email


Micrograph showing AML
Image from Armed Forces Institute of Pathology
The AP-1 transcription factor family is of “major importance” in acute myeloid leukemia (AML), according to researchers. The team said they identified transcription factor networks specific to AML subtypes, which showed that leukemic growth is dependent upon certain transcription factors, and “the global activation... [Read Article]
Print Friendly, PDF & Email

‘Compelling’ new target found for monocytic AML

Print Friendly, PDF & Email


Chengcheng “Alec” Zhang, PhD
Photo from University of Texas Southwestern Medical Center
Efforts to determine why immune checkpoint blockade is not successful in treating leukemia have resulted in a “compelling” new target to treat monocytic acute myeloid leukemia (AML), according to researchers. They discovered that leukocyte immunoglobulin-like receptor B4 (LILRB4), a marker of monocytic... [Read Article]
Print Friendly, PDF & Email

Quizartinib receives accelerated assessment for AML

Print Friendly, PDF & Email


Micrograph showing AML
Image from Paulo
Henrique Orlandi Mourao
The European Medicines Agency has granted accelerated assessment to the marketing authorization application (MAA) for the FLT3 inhibitor quizartinib. With this MAA, Daiichi Sankyo Company, Ltd., is seeking authorization for quizartinib to treat adults with FLT3-ITD-positive, relapsed or refractory acute myeloid leukemia (AML). Accelerated assessment... [Read Article]
Print Friendly, PDF & Email

Changes related to AML relapse may be reversible

Print Friendly, PDF & Email


AML cells
New research suggests relapse of acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplant (HSCT) is related to changes in immune-related gene expression that may be reversible. Researchers observed downregulation of major histocompatibility complex (MHC) class II genes in samples from patients who relapsed after HSCT. However, interferon-gamma “rapidly reversed this... [Read Article]
Print Friendly, PDF & Email

EVI1 overexpression promotes leukemogenesis, study suggests

Print Friendly, PDF & Email


AML cells
Image by Lance Liotta
Preclinical research suggests the oncoprotein EVI1 can promote leukemogenesis by suppressing erythropoiesis and lymphopoiesis while shifting differentiation toward the expansion of myeloid cells. Researchers developed a new mouse model that mimics chromosomal rearrangements at 3q26, which are associated with poor-prognosis acute myeloid leukemia (AML), myelodysplastic syndromes, and myeloproliferative... [Read Article]
Print Friendly, PDF & Email

Fusion protein identified as new target in AML

Print Friendly, PDF & Email


Lab mice
Photo by Aaron Logan
Researchers have identified a promising therapeutic target for t(8;21) acute myeloid leukemia (AML), according to preclinical data published in Cancer Cell. The fusion protein RUNX1/ETO drives t(8;21) AML by promoting cell-cycle progression. Using an RNAi screen, the team recognized the cell-cycle regulator cyclin D2 (CCND2) as having critical involvement... [Read Article]
Print Friendly, PDF & Email